Novel Benzo[b][1,5] naphthyridine–Arylhydrazone Hybrids as EGFR-Targeted Anticancer Agents: Synthesis, DFT, and MCF-7 Antiproliferative Evaluation

Technical Summary: Novel Benzo[b][1,5]naphthyridine–Arylhydrazone Hybrids as EGFR-Targeted Anticancer Agents

Problem Statement
Breast cancer, particularly the estrogen receptor-positive (ER+) MCF-7 subtype, remains a leading cause of cancer-related mortality. Despite existing therapies, challenges such as multidrug resistance, systemic toxicity, and disease relapse necessitate the development of structurally novel small-molecule anticancer agents. While nitrogen-containing heterocycles like quinoline and pyridine are established pharmacophores in drugs such as irinotecan, cabozantinib, and imatinib, the tricyclic pyridoquinoline (benzo[b][1,5]naphthyridine) scaffold remains largely unexplored in anticancer design. Furthermore, the integration of hydrazone linkages, known for their rigidity and metal-chelating properties, with this specific scaffold has not been systematically investigated for Epidermal Growth Factor Receptor (EGFR) targeting.

Methodology
The study employed a multidisciplinary approach combining synthetic chemistry, in vitro biological evaluation, and computational modeling:

1. Synthesis and Characterization: Six novel arylhydrazone derivatives (3a–f) were synthesized via a two-step sequence. First, 7,10-dichloro-2-methoxybenzo[b][1,5]naphthyridine underwent selective nucleophilic aromatic substitution (SNAr) with hydrazine hydrate to yield intermediate 2. Second, intermediate 2 was condensed with six electronically diverse aromatic aldehydes (varying substituents: –N(CH₃)₂, –H, –OCH₃, –Cl, –NO₂) under acid catalysis. The structures were confirmed using IR, ¹H/¹³C NMR, and ESI-MS spectroscopy.
2. Biological Evaluation: The antiproliferative activity of compounds 3a–f was assessed against the MCF-7 human breast cancer cell line using the MTT assay (48-hour incubation). Ellipticine served as the reference standard.
3. Molecular Docking: Compounds were docked into the EGFR kinase ATP-binding site (PDB: 3EQM) using the Glide module (Schrödinger). The study analyzed binding affinities, interaction maps (π–π stacking, hydrogen bonds, electrostatic contacts), and validated the protocol by re-docking the co-crystallized ligand.
4. Normal Mode Analysis (NMA): To validate the stability of the most potent complex (3a–EGFR), NMA-based molecular dynamics simulations were performed using the iMODS server. Parameters included deformability, B-factors, eigenvalues, variance distribution, and covariance maps.
5. DFT Calculations: Density Functional Theory calculations at the B3LYP/6-311G(d,p) level were conducted to determine frontier molecular orbital energies (HOMO/LUMO), global reactivity descriptors (hardness, softness, electrophilicity), dipole moments, and molecular electrostatic potential (MEP) surfaces.

Key Results

• Synthesis: All six target compounds (3a–f) were obtained in 80–95% yields. Spectroscopic data confirmed the formation of (E)-configured arylhydrazone derivatives with the benzo[b][1,5]naphthyridine core intact.
• Biological Activity: Compound 3a, bearing a 4-(dimethylamino)phenyl substituent, exhibited the highest potency with an IC₅₀ of 1.02 ± 0.36 μM. The activity trend followed the order: 3a > 3e > 3f > 3c > 3d > 3b. This indicates that strong electron-donating groups at the para-position of the hydrazone aryl ring significantly enhance antiproliferative activity. Compound 3a was more potent than the unsubstituted analog (3b, IC₅₀ = 25.13 μM) and showed comparable or superior activity to the reference ellipticine (IC₅₀ = 0.22 μM) in the context of selectivity and binding.
• Molecular Docking: Compound 3a achieved the highest docking score (–8.166 kcal/mol), surpassing ellipticine (–6.698 kcal/mol). The binding mode involved extensive π–π stacking with Trp224 and Phe221, hydrophobic contacts with Phe430 and Met364, and electrostatic interactions with Arg115, Glu302, and Asp309. Compound 3e also showed strong binding (–7.888 kcal/mol), featuring a critical hydrogen bond with the gatekeeper residue Thr310.
• NMA Simulations: The 3a–EGFR complex demonstrated structural rigidity in the ATP-binding pocket (low deformability) and a low first eigenvalue (3.245865 × 10⁻⁴), indicating a stable, low-energy collective motion. The covariance map revealed cooperative domain motions consistent with productive ligand-induced conformational selection.
• DFT Analysis: Compound 3a displayed the smallest HOMO–LUMO energy gap (1.5922 eV), the highest chemical softness (1.2561 eV⁻¹), and the largest dipole moment (8.0136 D). These electronic properties correlate with its superior charge-transfer capabilities and binding affinity. The high dipole moment of 3a facilitates strong electrostatic interactions with the charged residues in the EGFR active site.

Significance and Claims
The paper establishes that the benzo[b][1,5]naphthyridine–arylhydrazone chemotype is a promising scaffold for EGFR-targeted anticancer drug discovery. The study claims that the integration of a planar pyridoquinoline core with a hydrazone linker, specifically functionalized with strong electron-donating groups (like the 4-dimethylamino moiety in 3a), optimizes the electronic and steric properties required for high-affinity binding to the EGFR ATP-binding pocket.

The authors assert that compound 3a represents a lead candidate due to its:

1. Superior in vitro potency against MCF-7 cells.
2. Enhanced binding affinity and interaction network compared to the reference drug ellipticine.
3. Favorable electronic descriptors (low HOMO–LUMO gap, high softness) that support effective charge transfer.
4. Validated stability in the EGFR binding site through NMA simulations.

The work concludes that this pharmacophoric hybridization strategy effectively addresses the need for novel EGFR inhibitors and proposes compound 3a for further optimization, ADMET profiling, and in vivo evaluation. The study does not claim clinical efficacy but positions 3a as a robust lead for future drug development pipelines.